HKG:2228

2 stories mentioning HKG:2228Updated 26d ago

Every FINWIRES story that references HKG:2228, newest first.

XtalPi Signs Drug Development Agreement with Potential Value of Over $400 Million

XtalPi (HKG:2228) entered into a partnership with an international biopharmaceutical company to develop an oral small-molecule therapy targeting a G protein-coupled receptor, according to a Tuesday Hong Kong bourse filing.The agreement carries a potential value of more than $400 million, including an upfront payment, research funding, development and commercial milestone payments, and future royalties.Under the deal, the partner will fully fund XtalPi's early-stage research and development work.Shares of the firm were down over 2% in late morning trade on Wednesday.

HKG:2228

Asia40d ago

XtalPi Receives Further $19 Million Under Drug Discovery Agreement With DoveTree

XtalPi Holdings (HKG:2228) said it received a further $19 million payment from DoveTree Medicines under an AI-driven drug discovery services agreement, according to a Wednesday filing with the Hong Kong bourse.The bio-tech platform's shares gained over 3% recent trade.The firm had previously agreed to use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas that would then be licensed to DoveTree.XtalPi received an upfront payment of $51 million at the time and is eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales.

HKG:2228

Track with the FINWIRES app suite

FolioX

Track HKG:2228 in your portfolio

WheelAI

Analyze HKG:2228 options with the wheel strategy

StockInsider

See market sentiment on HKG:2228